<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37838698</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>14</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Mitigating a TDP-43 proteinopathy by targeting ataxin-2 using RNA-targeting CRISPR effector proteins.</ArticleTitle><Pagination><StartPage>6492</StartPage><MedlinePgn>6492</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">6492</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-023-42147-z</ELocationID><Abstract><AbstractText>The TDP-43 proteinopathies, which include amyotrophic lateral sclerosis and frontotemporal dementia, are a devastating group of neurodegenerative disorders that are characterized by the mislocalization and aggregation of TDP-43. Here we demonstrate that RNA-targeting CRISPR effector proteins, a programmable class of gene silencing agents that includes the Cas13 family of enzymes and Cas7-11, can be used to mitigate TDP-43 pathology when programmed to target ataxin-2, a modifier of TDP-43-associated toxicity. In addition to inhibiting the aggregation and transit of TDP-43 to stress granules, we find that the in vivo delivery of an ataxin-2-targeting Cas13 system to a mouse model of TDP-43 proteinopathy improved functional deficits, extended survival, and reduced the severity of neuropathological hallmarks. Further, we benchmark RNA-targeting CRISPR platforms against ataxin-2 and find that high-fidelity forms of Cas13 possess improved transcriptome-wide specificity compared to Cas7-11 and a first-generation effector. Our results demonstrate the potential of CRISPR technology for TDP-43 proteinopathies.</AbstractText><CopyrightInformation>&#xa9; 2023. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zeballos C</LastName><ForeName>M Alejandra</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-5194-2909</Identifier><AffiliationInfo><Affiliation>Department of Bioengineering, University of Illinois Urbana-Champaign, Urbana, IL, 61801, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Hayden J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, University of Illinois Urbana-Champaign, Urbana, IL, 61801, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Tyler J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, University of Illinois Urbana-Champaign, Urbana, IL, 61801, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Powell</LastName><ForeName>Jackson E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, University of Illinois Urbana-Champaign, Urbana, IL, 61801, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahsan</LastName><ForeName>Najah S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, University of Illinois Urbana-Champaign, Urbana, IL, 61801, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Sijia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, University of Illinois Urbana-Champaign, Urbana, IL, 61801, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaj</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-6004-9664</Identifier><AffiliationInfo><Affiliation>Department of Bioengineering, University of Illinois Urbana-Champaign, Urbana, IL, 61801, USA. gaj@illinois.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Carl R. Woese Institute for Genomic Biology, University of Illinois Urbana-Champaign, Urbana, IL, 61801, USA. gaj@illinois.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>figshare</DataBankName><AccessionNumberList><AccessionNumber>10.6084/m9.figshare.24187503</AccessionNumber><AccessionNumber>10.6084/m9.figshare.24195102</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>1U01NS122102-01A1</GrantID><Agency>U.S. Department of Health &amp;amp; Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)</Agency><Country/></Grant><Grant><GrantID>1R01NS123556-01A1</GrantID><Agency>U.S. Department of Health &amp;amp; Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)</Agency><Country/></Grant><Grant><GrantID>5R01GM141296</GrantID><Agency>U.S. Department of Health &amp;amp; Human Services | NIH | National Institute of General Medical Sciences (NIGMS)</Agency><Country/></Grant><Grant><GrantID>T32EB019944</GrantID><Agency>U.S. Department of Health &amp;amp; Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (NIBIB)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067698">Ataxin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578077">TDP-43 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>bioRxiv. 2023 Aug 26;:</RefSource><PMID Version="1">37066174</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067698" MajorTopicYN="N">Ataxin-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057177" MajorTopicYN="Y">TDP-43 Proteinopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>T.G. and J.P. filed a pending international patent application (PCT/US2022/036494) on the methods used in this manuscript. No part of this study is included in the filed patent application. The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>23</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>15</Day><Hour>5</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>14</Day><Hour>23</Hour><Minute>19</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37838698</ArticleId><ArticleId IdType="pmc">PMC10576788</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-42147-z</ArticleId><ArticleId IdType="pii">10.1038/s41467-023-42147-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ling S-C, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79:416&#x2013;438. doi: 10.1016/j.neuron.2013.07.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.033</ArticleId><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis withSOD1 mutations. Ann. Neurol. 2007;61:427&#x2013;434. doi: 10.1002/ana.21147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21147</ArticleId><ArticleId IdType="pubmed">17469116</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2006;351:602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Cleveland DW. Rethinking ALS: The FUS about TDP-43. Cell. 2009;136:1001&#x2013;1004. doi: 10.1016/j.cell.2009.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2009.03.006</ArticleId><ArticleId IdType="pmc">PMC3110083</ArticleId><ArticleId IdType="pubmed">19303844</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Feldman HH. Ubiquitin immunohistochemistry suggests classic motor neuron disease, motor neuron disease with dementia, and frontotemporal dementia of the motor neuron disease type represent a clinicopathologic spectrum. J. Neuropathol. Exp. Neurol. 2005;64:730&#x2013;739. doi: 10.1097/01.jnen.0000174335.27708.0a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.jnen.0000174335.27708.0a</ArticleId><ArticleId IdType="pubmed">16106222</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N. Engl. J. Med. 2001;344:1688&#x2013;1700. doi: 10.1056/NEJM200105313442207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200105313442207</ArticleId><ArticleId IdType="pubmed">11386269</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat. Neurosci. 2011;14:459&#x2013;468. doi: 10.1038/nn.2779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2779</ArticleId><ArticleId IdType="pmc">PMC3094729</ArticleId><ArticleId IdType="pubmed">21358643</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BS, McCaffery JM, Lindquist S, Gitler AD. A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc. Natl. Acad. Sci. USA. 2008;105:6439&#x2013;6444. doi: 10.1073/pnas.0802082105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0802082105</ArticleId><ArticleId IdType="pmc">PMC2359814</ArticleId><ArticleId IdType="pubmed">18434538</ArticleId></ArticleIdList></Reference><Reference><Citation>Winton MJ, et al. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J. Biol. Chem. 2008;283:13302&#x2013;13309. doi: 10.1074/jbc.M800342200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M800342200</ArticleId><ArticleId IdType="pmc">PMC2442318</ArticleId><ArticleId IdType="pubmed">18305110</ArticleId></ArticleIdList></Reference><Reference><Citation>Pesiridis GS, Lee VM-Y, Trojanowski JQ. Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. Hum. Mol. Genet. 2009;18:R156&#x2013;R162. doi: 10.1093/hmg/ddp303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp303</ArticleId><ArticleId IdType="pmc">PMC2758707</ArticleId><ArticleId IdType="pubmed">19808791</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672. doi: 10.1126/science.1154584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1154584</ArticleId><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, et al. TARDBP variation associated with frontotemporal dementia, supranuclear gaze palsy, and chorea: TARDBP Variation and Frontotemporal Dementia. Mov. Disord. 2009;24:1842&#x2013;1847. doi: 10.1002/mds.22697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22697</ArticleId><ArticleId IdType="pubmed">19609911</ArticleId></ArticleIdList></Reference><Reference><Citation>Benajiba L, et al. TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Ann. Neurol. 2009;65:470&#x2013;473. doi: 10.1002/ana.21612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21612</ArticleId><ArticleId IdType="pubmed">19350673</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen TJ, Lee VMY, Trojanowski JQ. TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies. Trends Mol. Med. 2011;17:659&#x2013;667. doi: 10.1016/j.molmed.2011.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2011.06.004</ArticleId><ArticleId IdType="pmc">PMC3202652</ArticleId><ArticleId IdType="pubmed">21783422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraemer BC, et al. Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. Acta Neuropathol. (Berl.) 2010;119:409&#x2013;419. doi: 10.1007/s00401-010-0659-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0659-0</ArticleId><ArticleId IdType="pmc">PMC2880609</ArticleId><ArticleId IdType="pubmed">20198480</ArticleId></ArticleIdList></Reference><Reference><Citation>Feiguin F, et al. Depletion of TDP-43 affects Drosophila motoneurons terminal synapsis and locomotive behavior. FEBS Lett. 2009;583:1586&#x2013;1592. doi: 10.1016/j.febslet.2009.04.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2009.04.019</ArticleId><ArticleId IdType="pubmed">19379745</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, C. et al. Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA111, E1121&#x2013;E1129 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3970502</ArticleId><ArticleId IdType="pubmed">24616503</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzog JJ, Deshpande M, Shapiro L, Rodal AA, Paradis S. TDP-43 misexpression causes defects in dendritic growth. Sci. Rep. 2017;7:15656. doi: 10.1038/s41598-017-15914-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-15914-4</ArticleId><ArticleId IdType="pmc">PMC5688077</ArticleId><ArticleId IdType="pubmed">29142232</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069&#x2013;1075. doi: 10.1038/nature09320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09320</ArticleId><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes LR, Kalab P. Emerging therapies and novel targets for TDP-43 proteinopathy in ALS/FTD. Neurotherapeutics. 2022;19:1061&#x2013;1084. doi: 10.1007/s13311-022-01260-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-022-01260-5</ArticleId><ArticleId IdType="pmc">PMC9587158</ArticleId><ArticleId IdType="pubmed">35790708</ArticleId></ArticleIdList></Reference><Reference><Citation>Armakola M, et al. Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models. Nat. Genet. 2012;44:1302&#x2013;1309. doi: 10.1038/ng.2434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2434</ArticleId><ArticleId IdType="pmc">PMC3510335</ArticleId><ArticleId IdType="pubmed">23104007</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H-J, et al. Therapeutic modulation of eIF2&#x3b1; phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nat. Genet. 2014;46:152&#x2013;160. doi: 10.1038/ng.2853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2853</ArticleId><ArticleId IdType="pmc">PMC3934366</ArticleId><ArticleId IdType="pubmed">24336168</ArticleId></ArticleIdList></Reference><Reference><Citation>Couthouis J, et al. A yeast functional screen predicts new candidate ALS disease genes. Proc. Natl. Acad. Sci. USA. 2011;108:20881&#x2013;20890. doi: 10.1073/pnas.1109434108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1109434108</ArticleId><ArticleId IdType="pmc">PMC3248518</ArticleId><ArticleId IdType="pubmed">22065782</ArticleId></ArticleIdList></Reference><Reference><Citation>Nihei Y, Ito D, Suzuki N. Roles of ataxin-2 in pathological cascades mediated by TAR DNA-binding protein 43 (TDP-43) and fused in sarcoma (FUS) J. Biol. Chem. 2012;287:41310&#x2013;41323. doi: 10.1074/jbc.M112.398099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.398099</ArticleId><ArticleId IdType="pmc">PMC3510829</ArticleId><ArticleId IdType="pubmed">23048034</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker LA, et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544:367&#x2013;371. doi: 10.1038/nature22038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22038</ArticleId><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Satterfield TF, Pallanck LJ. Ataxin-2 and its Drosophila homolog, ATX2, physically assemble with polyribosomes. Hum. Mol. Genet. 2006;15:2523&#x2013;2532. doi: 10.1093/hmg/ddl173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddl173</ArticleId><ArticleId IdType="pubmed">16835262</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonhoff U, et al. Ataxin-2 interacts with the DEAD/H-box RNA helicase DDX6 and interferes with P-bodies and stress granules. Mol. Biol. Cell. 2007;18:1385&#x2013;1396. doi: 10.1091/mbc.e06-12-1120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.e06-12-1120</ArticleId><ArticleId IdType="pmc">PMC1838996</ArticleId><ArticleId IdType="pubmed">17392519</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewey CM, et al. TDP-43 is directed to stress granules by sorbitol, a novel physiological osmotic and oxidative stressor. Mol. Cell. Biol. 2011;31:1098&#x2013;1108. doi: 10.1128/MCB.01279-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.01279-10</ArticleId><ArticleId IdType="pmc">PMC3067820</ArticleId><ArticleId IdType="pubmed">21173160</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross OA, et al. Ataxin-2 repeat-length variation and neurodegeneration. Hum. Mol. Genet. 2011;20:3207&#x2013;3212. doi: 10.1093/hmg/ddr227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr227</ArticleId><ArticleId IdType="pmc">PMC3140823</ArticleId><ArticleId IdType="pubmed">21610160</ArticleId></ArticleIdList></Reference><Reference><Citation>Gispert S, et al. The modulation of Amyotrophic Lateral Sclerosis risk by Ataxin-2 intermediate polyglutamine expansions is a specific effect. Neurobiol. Dis. 2012;45:356&#x2013;361. doi: 10.1016/j.nbd.2011.08.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2011.08.021</ArticleId><ArticleId IdType="pubmed">21889984</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee T, et al. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Hum. Mol. Genet. 2011;20:1697&#x2013;1700. doi: 10.1093/hmg/ddr045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr045</ArticleId><ArticleId IdType="pmc">PMC3071667</ArticleId><ArticleId IdType="pubmed">21292779</ArticleId></ArticleIdList></Reference><Reference><Citation>Daoud, H. et al. Association of long ATXN2 CAG repeat sizes with increased risk of amyotrophic lateral sclerosis. Arch. Neurol. 68, 739&#x2013;742 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21670397</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, et al. Ataxin-2 intermediate-length polyglutamine: a possible risk factor for Chinese patients with amyotrophic lateral sclerosis. Neurobiol. Aging. 2011;32:1925.e1&#x2013;1925.e5. doi: 10.1016/j.neurobiolaging.2011.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.05.015</ArticleId><ArticleId IdType="pubmed">21741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Langenhove T, et al. Ataxin-2 polyQ expansions in FTLD-ALS spectrum disorders in Flanders-Belgian cohorts. Neurobiol. Aging. 2012;33:1004.e17&#x2013;1004.e20. doi: 10.1016/j.neurobiolaging.2011.09.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.09.025</ArticleId><ArticleId IdType="pubmed">22035589</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinek M, et al. A programmable dual-RNA&#x2013;guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816&#x2013;821. doi: 10.1126/science.1225829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1225829</ArticleId><ArticleId IdType="pmc">PMC6286148</ArticleId><ArticleId IdType="pubmed">22745249</ArticleId></ArticleIdList></Reference><Reference><Citation>Cong L, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339:819&#x2013;823. doi: 10.1126/science.1231143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1231143</ArticleId><ArticleId IdType="pmc">PMC3795411</ArticleId><ArticleId IdType="pubmed">23287718</ArticleId></ArticleIdList></Reference><Reference><Citation>Sander JD, Joung JK. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat. Biotechnol. 2014;32:347&#x2013;355. doi: 10.1038/nbt.2842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.2842</ArticleId><ArticleId IdType="pmc">PMC4022601</ArticleId><ArticleId IdType="pubmed">24584096</ArticleId></ArticleIdList></Reference><Reference><Citation>Abudayyeh OO, et al. RNA targeting with CRISPR&#x2013;Cas13. Nature. 2017;550:280&#x2013;284. doi: 10.1038/nature24049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24049</ArticleId><ArticleId IdType="pmc">PMC5706658</ArticleId><ArticleId IdType="pubmed">28976959</ArticleId></ArticleIdList></Reference><Reference><Citation>Abudayyeh OO, et al. C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science. 2016;353:aaf5573. doi: 10.1126/science.aaf5573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf5573</ArticleId><ArticleId IdType="pmc">PMC5127784</ArticleId><ArticleId IdType="pubmed">27256883</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox DBT, et al. RNA editing with CRISPR-Cas13. Science. 2017;358:1019&#x2013;1027. doi: 10.1126/science.aaq0180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaq0180</ArticleId><ArticleId IdType="pmc">PMC5793859</ArticleId><ArticleId IdType="pubmed">29070703</ArticleId></ArticleIdList></Reference><Reference><Citation>Smargon AA, et al. Cas13b is a type VI-B CRISPR-associated RNA-guided RNase differentially regulated by accessory proteins Csx27 and Csx28. Mol. Cell. 2017;65:618&#x2013;630.e7. doi: 10.1016/j.molcel.2016.12.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2016.12.023</ArticleId><ArticleId IdType="pmc">PMC5432119</ArticleId><ArticleId IdType="pubmed">28065598</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan WX, et al. Cas13d is a compact RNA-targeting type VI CRISPR effector positively modulated by a WYL-domain-containing accessory protein. Mol. Cell. 2018;70:327&#x2013;339.e5. doi: 10.1016/j.molcel.2018.02.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2018.02.028</ArticleId><ArticleId IdType="pmc">PMC5935466</ArticleId><ArticleId IdType="pubmed">29551514</ArticleId></ArticleIdList></Reference><Reference><Citation>Konermann S, et al. Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors. Cell. 2018;173:665&#x2013;676.e14. doi: 10.1016/j.cell.2018.02.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.02.033</ArticleId><ArticleId IdType="pmc">PMC5910255</ArticleId><ArticleId IdType="pubmed">29551272</ArticleId></ArticleIdList></Reference><Reference><Citation>East-Seletsky A, et al. Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection. Nature. 2016;538:270&#x2013;273. doi: 10.1038/nature19802.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature19802</ArticleId><ArticleId IdType="pmc">PMC5576363</ArticleId><ArticleId IdType="pubmed">27669025</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;zcan A, et al. Programmable RNA targeting with the single-protein CRISPR effector Cas7-11. Nature. 2021;597:720&#x2013;725. doi: 10.1038/s41586-021-03886-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03886-5</ArticleId><ArticleId IdType="pubmed">34489594</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, et al. TIA1 mutations in amyotrophic lateral sclerosis and frontotemporal dementia promote phase separation and alter stress granule dynamics. Neuron. 2017;95:808&#x2013;816.e9. doi: 10.1016/j.neuron.2017.07.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.07.025</ArticleId><ArticleId IdType="pmc">PMC5576574</ArticleId><ArticleId IdType="pubmed">28817800</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems S, et al. Phase separation of C9orf72 dipeptide repeats perturbs stress granule dynamics. Mol. Cell. 2017;65:1044&#x2013;1055.e5. doi: 10.1016/j.molcel.2017.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2017.02.013</ArticleId><ArticleId IdType="pmc">PMC5364369</ArticleId><ArticleId IdType="pubmed">28306503</ArticleId></ArticleIdList></Reference><Reference><Citation>Powell JE, et al. Targeted gene silencing in the nervous system with CRISPR-Cas13. Sci. Adv. 2022;8:eabk2485. doi: 10.1126/sciadv.abk2485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abk2485</ArticleId><ArticleId IdType="pmc">PMC8769545</ArticleId><ArticleId IdType="pubmed">35044815</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y, et al. Specific knockdown of Htra2 by CRISPR-CasRx prevents acquired sensorineural hearing loss in mice. Mol. Ther. - Nucleic Acids. 2022;28:643&#x2013;655. doi: 10.1016/j.omtn.2022.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2022.04.014</ArticleId><ArticleId IdType="pmc">PMC9112053</ArticleId><ArticleId IdType="pubmed">35615000</ArticleId></ArticleIdList></Reference><Reference><Citation>Morelli KH, et al. An RNA-targeting CRISPR&#x2013;Cas13d system alleviates disease-related phenotypes in Huntington&#x2019;s disease models. Nat. Neurosci. 2023;26:27&#x2013;38. doi: 10.1038/s41593-022-01207-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-022-01207-1</ArticleId><ArticleId IdType="pmc">PMC9829537</ArticleId><ArticleId IdType="pubmed">36510111</ArticleId></ArticleIdList></Reference><Reference><Citation>Ai Y, Liang D, Wilusz JE. CRISPR/Cas13 effectors have differing extents of off-target effects that limit their utility in eukaryotic cells. Nucleic Acids Res. 2022;50:e65&#x2013;e65. doi: 10.1093/nar/gkac159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkac159</ArticleId><ArticleId IdType="pmc">PMC9226543</ArticleId><ArticleId IdType="pubmed">35244715</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley CP, Haerle MC, Wang ET. Negative autoregulation mitigates collateral RNase activity of repeat-targeting CRISPR-Cas13d in mammalian cells. Cell Rep. 2022;40:111226. doi: 10.1016/j.celrep.2022.111226.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.111226</ArticleId><ArticleId IdType="pmc">PMC9809062</ArticleId><ArticleId IdType="pubmed">35977479</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, et al. The collateral activity of RfxCas13d can induce lethality in a RfxCas13d knock-in mouse model. Genome Biol. 2023;24:20. doi: 10.1186/s13059-023-02860-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-023-02860-w</ArticleId><ArticleId IdType="pmc">PMC9893547</ArticleId><ArticleId IdType="pubmed">36726140</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi P, et al. Collateral activity of the CRISPR/RfxCas13d system in human cells. Commun. Biol. 2023;6:334. doi: 10.1038/s42003-023-04708-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-023-04708-2</ArticleId><ArticleId IdType="pmc">PMC10049998</ArticleId><ArticleId IdType="pubmed">36977923</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, et al. The CRISPR&#x2010;Cas13a gene&#x2010;editing system induces collateral cleavage of RNA in glioma cells. Adv. Sci. 2019;6:1901299. doi: 10.1002/advs.201901299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.201901299</ArticleId><ArticleId IdType="pmc">PMC6794629</ArticleId><ArticleId IdType="pubmed">31637166</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombrita C, et al. TDP-43 is recruited to stress granules in conditions of oxidative insult. J. Neurochem. 2009;111:1051&#x2013;1061. doi: 10.1111/j.1471-4159.2009.06383.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06383.x</ArticleId><ArticleId IdType="pubmed">19765185</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker SJ, et al. Endogenous TDP-43 localized to stress granules can subsequently form protein aggregates. Neurochem. Int. 2012;60:415&#x2013;424. doi: 10.1016/j.neuint.2012.01.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2012.01.019</ArticleId><ArticleId IdType="pubmed">22306778</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu-Yesucevitz L, et al. Tar DNA binding protein-43 (tdp-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. PLoS ONE. 2010;5:e13250. doi: 10.1371/journal.pone.0013250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0013250</ArticleId><ArticleId IdType="pmc">PMC2952586</ArticleId><ArticleId IdType="pubmed">20948999</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewey CM, et al. TDP-43 aggregation in neurodegeneration: Are stress granules the key? Brain Res. 2012;1462:16&#x2013;25. doi: 10.1016/j.brainres.2012.02.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2012.02.032</ArticleId><ArticleId IdType="pmc">PMC3372581</ArticleId><ArticleId IdType="pubmed">22405725</ArticleId></ArticleIdList></Reference><Reference><Citation>Weskamp K, et al. Shortened TDP43 isoforms upregulated by neuronal hyperactivity drive TDP43 pathology in ALS. J. Clin. Invest. 2020;130:1139&#x2013;1155. doi: 10.1172/JCI130988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI130988</ArticleId><ArticleId IdType="pmc">PMC7269575</ArticleId><ArticleId IdType="pubmed">31714900</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T, Baldie G, Periz G, Wang J. RNA-processing protein TDP-43 regulates FOXO-dependent protein quality control in stress response. PLoS Genet. 2014;10:e1004693. doi: 10.1371/journal.pgen.1004693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1004693</ArticleId><ArticleId IdType="pmc">PMC4199500</ArticleId><ArticleId IdType="pubmed">25329970</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong, H. et al. High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects. Nat. Biotechnol. 10.1038/s41587-022-01419-7 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35953673</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter AE, et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 2006;7:R100. doi: 10.1186/gb-2006-7-10-r100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2006-7-10-r100</ArticleId><ArticleId IdType="pmc">PMC1794559</ArticleId><ArticleId IdType="pubmed">17076895</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidib&#xe9; H, et al. TDP-43 stabilizes G3BP1 mRNA: relevance to amyotrophic lateral sclerosis/frontotemporal dementia. Brain. 2021;144:3461&#x2013;3476. doi: 10.1093/brain/awab217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab217</ArticleId><ArticleId IdType="pmc">PMC8677511</ArticleId><ArticleId IdType="pubmed">34115105</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang P, et al. G3BP1 is a tunable switch that triggers phase separation to assemble stress granules. Cell. 2020;181:325&#x2013;345.e28. doi: 10.1016/j.cell.2020.03.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.03.046</ArticleId><ArticleId IdType="pmc">PMC7448383</ArticleId><ArticleId IdType="pubmed">32302571</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu-Yesucevitz L, et al. ALS-linked mutations enlarge TDP-43-enriched neuronal RNA granules in the dendritic arbor. J. Neurosci. 2014;34:4167&#x2013;4174. doi: 10.1523/JNEUROSCI.2350-13.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2350-13.2014</ArticleId><ArticleId IdType="pmc">PMC3960463</ArticleId><ArticleId IdType="pubmed">24647938</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling S-C, et al. ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. Proc. Natl. Acad. Sci. USA. 2010;107:13318&#x2013;13323. doi: 10.1073/pnas.1008227107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1008227107</ArticleId><ArticleId IdType="pmc">PMC2922163</ArticleId><ArticleId IdType="pubmed">20624952</ArticleId></ArticleIdList></Reference><Reference><Citation>Wils H, et al. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. USA. 2010;107:3858&#x2013;3863. doi: 10.1073/pnas.0912417107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0912417107</ArticleId><ArticleId IdType="pmc">PMC2840518</ArticleId><ArticleId IdType="pubmed">20133711</ArticleId></ArticleIdList></Reference><Reference><Citation>Foust KD, et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 2009;27:59&#x2013;65. doi: 10.1038/nbt.1515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1515</ArticleId><ArticleId IdType="pmc">PMC2895694</ArticleId><ArticleId IdType="pubmed">19098898</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarty P, et al. Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain. PLoS ONE. 2013;8:e67680. doi: 10.1371/journal.pone.0067680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0067680</ArticleId><ArticleId IdType="pmc">PMC3692458</ArticleId><ArticleId IdType="pubmed">23825679</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Meo I, Marchet S, Lamperti C, Zeviani M, Viscomi C. AAV9-based gene therapy partially ameliorates the clinical phenotype of a mouse model of Leigh syndrome. Gene Ther. 2017;24:661&#x2013;667. doi: 10.1038/gt.2017.53.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gt.2017.53</ArticleId><ArticleId IdType="pmc">PMC5658670</ArticleId><ArticleId IdType="pubmed">28753212</ArticleId></ArticleIdList></Reference><Reference><Citation>Armbruster N, et al. Efficacy and biodistribution analysis of intracerebroventricular administration of an optimized scAAV9-SMN1 vector in a mouse model of spinal muscular atrophy. Mol. Ther. - Methods Clin. Dev. 2016;3:16060. doi: 10.1038/mtm.2016.60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mtm.2016.60</ArticleId><ArticleId IdType="pmc">PMC5022869</ArticleId><ArticleId IdType="pubmed">27652289</ArticleId></ArticleIdList></Reference><Reference><Citation>Corr&#xe0; S, Cerutti R, Balmaceda V, Viscomi C, Zeviani M. Double administration of self-complementary AAV9 NDUFS4 prevents Leigh disease in Ndufs4 &#x2212;/&#x2212; mice. Brain. 2022;145:3405&#x2013;3414. doi: 10.1093/brain/awac182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac182</ArticleId><ArticleId IdType="pmc">PMC9586549</ArticleId><ArticleId IdType="pubmed">36270002</ArticleId></ArticleIdList></Reference><Reference><Citation>Damrath E, et al. ATXN2-CAG42 sequesters PABPC1 into insolubility and induces FBXW8 in cerebellum of old ataxic knock-in mice. PLoS Genet. 2012;8:e1002920. doi: 10.1371/journal.pgen.1002920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1002920</ArticleId><ArticleId IdType="pmc">PMC3431311</ArticleId><ArticleId IdType="pubmed">22956915</ArticleId></ArticleIdList></Reference><Reference><Citation>Inukai Y, et al. Abnormal phosphorylation of Ser409/410 of TDP-43 in FTLD-U and ALS. FEBS Lett. 2008;582:2899&#x2013;2904. doi: 10.1016/j.febslet.2008.07.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2008.07.027</ArticleId><ArticleId IdType="pubmed">18656473</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoshi M, et al. Direct Binding of Ataxin-2 to Distinct Elements in 3&#x2032; UTRs Promotes mRNA Stability and Protein Expression. Mol. Cell. 2014;55:186&#x2013;198. doi: 10.1016/j.molcel.2014.05.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2014.05.022</ArticleId><ArticleId IdType="pubmed">24954906</ArticleId></ArticleIdList></Reference><Reference><Citation>Rounds JC, et al. The disease-associated proteins Drosophila Nab2 and Ataxin-2 interact with shared RNAs and coregulate neuronal morphology. Genetics. 2022;220:iyab175. doi: 10.1093/genetics/iyab175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/genetics/iyab175</ArticleId><ArticleId IdType="pmc">PMC8733473</ArticleId><ArticleId IdType="pubmed">34791182</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuong Vi,DT, et al. Pbp1, the yeast ortholog of human Ataxin-2, functions in the cell growth on non-fermentable carbon sources. PLOS ONE. 2021;16:e0251456. doi: 10.1371/journal.pone.0251456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0251456</ArticleId><ArticleId IdType="pmc">PMC8118320</ArticleId><ArticleId IdType="pubmed">33984024</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Z, et al. Preventing autosomal-dominant hearing loss in Bth mice with CRISPR/CasRx-based RNA editing. Signal Transduct. Target. Ther. 2022;7:79. doi: 10.1038/s41392-022-00893-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00893-4</ArticleId><ArticleId IdType="pmc">PMC8918553</ArticleId><ArticleId IdType="pubmed">35283480</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith RA. Antisense oligonucleotide therapy for neurodegenerative disease. J. Clin. Invest. 2006;116:2290&#x2013;2296. doi: 10.1172/JCI25424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI25424</ArticleId><ArticleId IdType="pmc">PMC1518790</ArticleId><ArticleId IdType="pubmed">16878173</ArticleId></ArticleIdList></Reference><Reference><Citation>Foust KD, et al. Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol. Ther. 2013;21:2148&#x2013;2159. doi: 10.1038/mt.2013.211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2013.211</ArticleId><ArticleId IdType="pmc">PMC3863799</ArticleId><ArticleId IdType="pubmed">24008656</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim CKW, et al. Treatment of a mouse model of ALS by in vivo base editing. Mol. Ther. 2020;28:1177&#x2013;1189. doi: 10.1016/j.ymthe.2020.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2020.01.005</ArticleId><ArticleId IdType="pmc">PMC7132599</ArticleId><ArticleId IdType="pubmed">31991108</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne, C. et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc. Natl. Acad. Sci. USA110, E4530&#x2013;E4539 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Meijboom KE, et al. CRISPR/Cas9-mediated excision of ALS/FTD-causing hexanucleotide repeat expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro. Nat. Commun. 2022;13:6286. doi: 10.1038/s41467-022-33332-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33332-7</ArticleId><ArticleId IdType="pmc">PMC9587249</ArticleId><ArticleId IdType="pubmed">36271076</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran H, et al. Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide. Nat. Med. 2022;28:117&#x2013;124. doi: 10.1038/s41591-021-01557-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01557-6</ArticleId><ArticleId IdType="pmc">PMC8861976</ArticleId><ArticleId IdType="pubmed">34949835</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo X, et al. Transcriptome-wide Cas13 guide RNA design for model organisms and viral RNA pathogens. Cell Genomics. 2021;1:100001. doi: 10.1016/j.xgen.2021.100001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xgen.2021.100001</ArticleId><ArticleId IdType="pmc">PMC9164475</ArticleId><ArticleId IdType="pubmed">35664829</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessels H-H, et al. Massively parallel Cas13 screens reveal principles for guide RNA design. Nat. Biotechnol. 2020;38:722&#x2013;727. doi: 10.1038/s41587-020-0456-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-020-0456-9</ArticleId><ArticleId IdType="pmc">PMC7294996</ArticleId><ArticleId IdType="pubmed">32518401</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiehl T-R, et al. Generation and characterization of Sca2 (ataxin-2) knockout mice. Biochem. Biophys. Res. Commun. 2006;339:17&#x2013;24. doi: 10.1016/j.bbrc.2005.10.186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2005.10.186</ArticleId><ArticleId IdType="pubmed">16293225</ArticleId></ArticleIdList></Reference><Reference><Citation>Meierhofer D, Halbach M, &#x15e;en NE, Gispert S, Auburger G. Ataxin-2 (Atxn2)-knock-out mice show branched chain amino acids and fatty acids pathway alterations. Mol. Cell. Proteomics. 2016;15:1728&#x2013;1739. doi: 10.1074/mcp.M115.056770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.M115.056770</ArticleId><ArticleId IdType="pmc">PMC4858951</ArticleId><ArticleId IdType="pubmed">26850065</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales L, Gambhir Y, Bennett J, Stedman HH. Broader implications of progressive liver dysfunction and lethal sepsis in two boys following systemic high-dose AAV. Mol. Ther. 2020;28:1753&#x2013;1755. doi: 10.1016/j.ymthe.2020.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2020.07.009</ArticleId><ArticleId IdType="pmc">PMC7363592</ArticleId><ArticleId IdType="pubmed">32710826</ArticleId></ArticleIdList></Reference><Reference><Citation>Palazzi X, et al. Biodistribution and tolerability of AAV-PHP.B-CBh- SMN1 in wistar han rats and cynomolgus macaques reveal different toxicologic profiles. Hum. Gene Ther. 2022;33:175&#x2013;187. doi: 10.1089/hum.2021.116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2021.116</ArticleId><ArticleId IdType="pmc">PMC8885435</ArticleId><ArticleId IdType="pubmed">34931542</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinderer C, et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum. Gene Ther. 2018;29:285&#x2013;298. doi: 10.1089/hum.2018.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2018.015</ArticleId><ArticleId IdType="pmc">PMC5865262</ArticleId><ArticleId IdType="pubmed">29378426</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdera HC, Kuranda K, Mingozzi F. AAV vector immunogenicity in humans: a long journey to successful gene transfer. Mol. Ther. 2020;28:723&#x2013;746. doi: 10.1016/j.ymthe.2019.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2019.12.010</ArticleId><ArticleId IdType="pmc">PMC7054726</ArticleId><ArticleId IdType="pubmed">31972133</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartel, M., Schaffer, D. &amp; Buning, H. Enhancing the clinical potential of AAV vectors by capsid engineering to evade pre-existing immunity. Front. Microbiol. 2, 204 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3207363</ArticleId><ArticleId IdType="pubmed">22065962</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Wei X, Lin J, Ou L. A versatile toolkit for overcoming AAV immunity. Front. Immunol. 2022;13:991832. doi: 10.3389/fimmu.2022.991832.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.991832</ArticleId><ArticleId IdType="pmc">PMC9479010</ArticleId><ArticleId IdType="pubmed">36119036</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertl HCJ. Immunogenicity and toxicity of AAV gene therapy. Front. Immunol. 2022;13:975803. doi: 10.3389/fimmu.2022.975803.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.975803</ArticleId><ArticleId IdType="pmc">PMC9411526</ArticleId><ArticleId IdType="pubmed">36032092</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeballos CMA, Gaj T. Next-generation CRISPR technologies and their applications in gene and cell therapy. Trends Biotechnol. 2021;39:692&#x2013;705. doi: 10.1016/j.tibtech.2020.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibtech.2020.10.010</ArticleId><ArticleId IdType="pmc">PMC8166939</ArticleId><ArticleId IdType="pubmed">33277043</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray SJ, et al. Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum. Gene Ther. 2011;22:1143&#x2013;1153. doi: 10.1089/hum.2010.245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2010.245</ArticleId><ArticleId IdType="pmc">PMC3177952</ArticleId><ArticleId IdType="pubmed">21476867</ArticleId></ArticleIdList></Reference><Reference><Citation>Powell SK, Samulski RJ, McCown TJ. AAV capsid-promoter interactions determine CNS cell-selective gene expression in vivo. Mol. Ther. 2020;28:1373&#x2013;1380. doi: 10.1016/j.ymthe.2020.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2020.03.007</ArticleId><ArticleId IdType="pmc">PMC7210720</ArticleId><ArticleId IdType="pubmed">32213322</ArticleId></ArticleIdList></Reference><Reference><Citation>Scoles DR, et al. Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature. 2017;544:362&#x2013;366. doi: 10.1038/nature22044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22044</ArticleId><ArticleId IdType="pmc">PMC6625650</ArticleId><ArticleId IdType="pubmed">28405024</ArticleId></ArticleIdList></Reference><Reference><Citation>Oyston LJ, et al. Rapid in vitro quantification of TDP-43 and FUS mislocalisation for screening of gene variants implicated in frontotemporal dementia and amyotrophic lateral sclerosis. Sci. Rep. 2021;11:14881. doi: 10.1038/s41598-021-94225-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-94225-1</ArticleId><ArticleId IdType="pmc">PMC8295343</ArticleId><ArticleId IdType="pubmed">34290285</ArticleId></ArticleIdList></Reference><Reference><Citation>Keating SS, Bademosi AT, San Gil R, Walker AK. Aggregation-prone TDP-43 sequesters and drives pathological transitions of free nuclear TDP-43. Cell. Mol. Life Sci. 2023;80:95. doi: 10.1007/s00018-023-04739-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-023-04739-2</ArticleId><ArticleId IdType="pmc">PMC10023653</ArticleId><ArticleId IdType="pubmed">36930291</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009;4:44&#x2013;57. doi: 10.1038/nprot.2008.211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2008.211</ArticleId><ArticleId IdType="pubmed">19131956</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulsen T, De Vlieg J, Alkema W. BioVenn &#x2013; a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams. BMC Genomics. 2008;9:488. doi: 10.1186/1471-2164-9-488.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2164-9-488</ArticleId><ArticleId IdType="pmc">PMC2584113</ArticleId><ArticleId IdType="pubmed">18925949</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>